US EditionAusperBio Presents Interim Phase IIb AHB-137 Clinical Data in a Late-Breaking Abstract at EASL™ Congress 2025
- On May 7, 2025, AusperBio shared preliminary results from its ongoing Phase IIb clinical trial of AHB-137 at the EASL Congress held in Amsterdam.
- The study evaluates AHB-137, an investigational antisense oligonucleotide targeting HBeAg-negative chronic hepatitis B patients on nucleoside analog therapy for functional cure.
- The primary endpoint combined HBsAg below 0.05 IU/mL and HBV DNA under 10 IU/mL at end of treatment, with 66% in the 16-week arm and 75% in the 24-week arm achieving it.
- Among patients who reached the primary endpoint, more than 80% achieved HBsAg clearance by week 12, and 33% of those in the 16-week treatment group developed anti-HBs antibodies; additionally, the medication was generally well tolerated with a positive safety profile.
- These data reinforce AHB-137's promise as a foundation for functional cure, supporting AusperBio's advance toward HBV cure through its Med-Oligo ASO platform and global development efforts.
Insights by Ground AI
Does this summary seem wrong?
19 Articles
19 Articles
All
Left
Center
7
Right
Hanford Sentinel+18 Reposted by 18 other sources
AusperBio Presents Interim Phase IIb AHB-137 Clinical Data in a Late-Breaking Abstract at EASL™ Congress 2025
SAN FRANCISCO, May 7, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from its ongoing Phase IIb trial of AHB-137 in a…
Coverage Details
Total News Sources19
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
